AIDS AND MIRNAS

Application of massive parallel sequencing to microRNA profiling of cellular and molecular response to HIV-1 and HIV-2 infection and to modulation of integration

Coordinatore	FUNDACAO DA FACULDADE DE CIENCIAS DA UNIVERSIDADE DE LISBOA    more  Organization address address: CAMPO GRANDE EDIFICIO C1 PISO 3 city: LISBOA postcode: 1749016 contact info Titolo: Ms. Nome: Livia Cognome: Moreira Email: send email Telefono: 351218000000 Fax: 351218000000
Nazionalità Coordinatore	Portugal [PT]
Totale costo	45˙000 €
EC contributo	45˙000 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2009-RG
Funding Scheme	MC-ERG
Anno di inizio	2010
Periodo (anno-mese-giorno)	2010-07-01   -   2013-11-29

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	FUNDACAO DA FACULDADE DE CIENCIAS DA UNIVERSIDADE DE LISBOA  Organization address address: CAMPO GRANDE EDIFICIO C1 PISO 3 city: LISBOA postcode: 1749016 contact info Titolo: Ms. Nome: Livia Cognome: Moreira Email: send email Telefono: 351218000000 Fax: 351218000000	PT (LISBOA)	coordinator	45˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'miRNAs are key regulators of cell function and pathogen infection. The identification of miRNAs involved inHIV infection promises to offer unique insights into disease mechanisms and to help identify novel targets for therapy. However, the ability to perform an unbiased characterization of miRNA expression has only recently become possible through the use of massive parallel sequencing. This proposal aims to generate the first whole-genome map of miRNA expression during HIV-1 and HIV-2 infection in primary lymphocytes using these novel sequencing techniques. Furthermore, we will identify miRNAs associated with key steps of infection by combining sequencing with the use of drug inhibitors that block viral DNA integration. We expect to identify miRNAs required for the progression of viral infection, with potential for future use in anti-HIV therapy. Pathways associated with differential miRNA expression between HIV-1 and HIV-2 will provide insights into the mildness of HIV-2 infection, providing clues for new strategies against HIV-1.'